Immunotherapy for Epstein-Barr virus-associated malignancies

Drug News and Perspectives

Volumn 23, Issue 4, 2010, Pages 221-228

  Long, Heather M ^a   Parsonage, Gregory ^a   Fox, Christopher P ^a   Lee, Steven P ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CYCLOPHOSPHAMIDE; EPSTEIN BARR VIRUS VACCINE; FLUDARABINE; RITUXIMAB;

ADOPTIVE TRANSFER; BURKITT LYMPHOMA; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HODGKIN DISEASE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; NASOPHARYNX CARCINOMA; REVIEW; T CELL LYMPHOMA; VIRUS CARCINOGENESIS; VIRUS IMMUNITY;

EPSTEIN-BARR VIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOTHERAPY; LYMPHOPROLIFERATIVE DISORDERS; NEOPLASMS; ORGAN TRANSPLANTATION; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC; VIRUS LATENCY;

EID: 77954609522     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2010.23.4.1439500     Document Type: Review

References (77)

1. Kelly, G.L., Long, H.M., Stylianou, J. et al. An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog 2009, 5(3): e1000341.
2. Rickinson, A.B., Kieff, E. Epstein-Barr virus. In: Fields, B. et al. (Eds.). Fields Virology. Lippincott, Williams & Wilkins: Philadelphia, 2006, 2655-700.
3. Young, L., Alfieri, C., Hennessy, K. et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989, 321(16): 1080-5.
4. Starzl, T.E., Nalesnik, M.A., Porter, K.A. et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984, 1(8377): 583-7.
5. Bello, C., Sotomayor, E.M. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program 2007: 233-42.
6. Styczynski, J., Einsele, H., Gil, L., Ljungman, P. Outcome of treatment of Epstein-Barr virus- related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009, 11(5): 383-92.
7. Savoldo, B., Rooney, C.M., Quiros-Tejeira, R.E. et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant 2005, 5(3): 566-72.
8. Cartron, G., Blasco, H., Paintaud, G., Watier, H., Le Guellec, C. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 2007, 62(1): 43-52.
9. Dharnidharka, V.R., Green, M., Webber, S.A. et al. Post-Transplant Lymphoproliferative Disorders. 1st ed. Dharnidharka, V.R., Green, M., Webber, S.A. (Eds.). Springer: Berlin Heidelberg, 2010.
10. Moss, P., Rickinson, A. Cellular immunotherapy for viral infection after HSC transplantation. Nat Rev Immunol 2005, 5(1): 9-20. (Pubitemid 40070327)
11. Papadopoulos, E.B., Ladanyi, M., Emanuel, D. et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone morrow transplantation. N Engl J Med 1994, 330(17): 1185-91. (Pubitemid 24121987)
12. Rooney, C.M., Smith, C.A., Ng, C.Y. et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995, 345(8941): 9-13.
13. Heslop, H.E., Slobod, K.S., Pule, M.A. et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2009, 115(5): 925-35.
14. Stanevsky, A., Goldstein, G., Nagler, A. Umbilical cord blood transplantation: pros, cons and beyond. Blood Rev 2009, 23(5): 199-204.
15. Cheng, F.W., Lee, V., To, K.F., Chan, K.C., Shing, M.K., Li, C.K. Post-transplant EBV- related lymphoproliferative disorder complicating umbilical cord blood transplantation in patients of adrenoleukodystrophy. Pediatr Blood Cancer 2009, 53(7): 1329-31.
16. Hanley, P.J., Cruz, C.R., Savoldo, B. et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009, 114(9): 1958-67.
17. Khanna, R., Bell, S., Sherritt, M. et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A 1999, 96(18): 10391-6.
18. Haque, T., Amlot, P.L., Helling, N. et al. Reconstitution of EBV-specific T cell Immunity in solid organ transplant recipients. J Immunol 1998, 160(12): 6204-9.
19. Brewin, J., Mancao, C., Straathof, K., Karlsson, H., Samarasinghe, S., Amrolia, P.J., Pule, M. Generation of EBV-specific cytotoxic T cells that are resistant to calclneurin inhibitors for the treatment of posttransplantation lymphoproliferative disease. Blood 2009, 114(23): 4792-803.
20. De Angelis, B., Dotti, G., Quintarelli, C. et al. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood 2009, 114(23): 4784-91.
21. Haque, T., Wilkie, G.M., Jones, M.M. et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007, 110(4): 1123-31.
22. Curado, M.P., Edwards, B., Shin, H.R., Storm, H., Ferlay, J., Heanue, M., Boyle, P. (Eds.) Cancer Incidence in Five Continents, Vol. IX. IARC Scientific Publications No. 160. International Agency for Research on Cancer: Lyon, 2007.
23. Haigh, T.A., Lin, X., Jia, H., Hui, E.P., Chan, A.T., Rickinson, A.B., Taylor, G.S. EBV latent membrane proteins (LMPs) 1 and 2 as immunotherapeutic targets: LMP-specific CD4+ cytotoxic T cell recognition of EBV-transformed B cell lines. J Immunol 2008, 180(3): 1643-54.
24. Hislop, A.D., Taylor, G.S., Sauce, D., Rickinson, A.B. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 2007, 25: 587-617.
25. Long, H.M., Haigh, T.A., Gudgeon, N.H. et al. CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J Virol 2005, 79(8): 4896-907.
26. Mautner, J., Pich, D., Nimmerjahn, F. et al. Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells. Eur J Immunol 2004, 34(9): 2500-9.
27. Fogg, M.H., Wirth, L.J., Posner, M., Wang, F. Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma. Proc Natl Acad Sci U S A 2009, 106(9): 3318-23.
28. Heller, K.N., Arrey, F., Steinherz, P., Portlock, C., Chadburn, A., Kelly, K., Munz, C. Patients with Epstein Barr virus-positive lymphomas have decreased CD4(+) T-cell responses to the viral nuclear antigen 1. Int J Cancer 2008, 123(12): 2824-31.
29. Chapman, A.L., Rickinson, A.B., Thomas, W.A., Jarrett, R.F., Crocker, J., Lee, S.P. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy. Cancer Res 2001, 61(16): 6219-26.
30. Lin, X., Gudgeon, N.H., Hui, E.P. et al. CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients. Cancer Immunol Immunother 2008, 57(7): 963-75.
31. Lin, C.L., Lo, W.F., Lee, T.H. et al. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 2002, 62(23): 6952-8.
32. Taylor, G.S., Haigh, T.A., Gudgeon, N.H., Phelps, R.J., Lee, S.P., Steven, N.M., Rickinson, A.B. Dual stimulation of Epstein- Barr Virus (EBV)-specific CD4+- and CD8+-T- cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma. J Virol 2004, 78(2): 768-78.
33. Lutzky, V.P., Corban, M., Heslop, L. et al. Novel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccine. J Virol 2009, 84(1): 407-17.
34. Bollard, C.M., Aguilar, L., Straathof, K.C. et al. Cytotoxic T lymphocyte therapy for Epstein- Barr virus+ Hodgkin's disease. J Exp Med 2004, 200(12): 1623-33. (Pubitemid 40094186)
35. Comoli, P., Pedrazzoli, P., Maccario, R. et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 2005, 23(35): 8942-9. (Pubitemid 46211479)
36. Louis, C.U., Straathof, K., Bollard, C.M. et al. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood 2009, 113(11): 2442-50.
37. Straathof, K.C., Bollard, C.M., Popat, U. et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005, 105(5): 1898-904. (Pubitemid 40731770)
38. Chua, D., Huang, J., Zheng, B. et al. Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int J Cancer 2001, 94(1): 73-80. (Pubitemid 32801755)
39. Comoli, P., De Palma, R., Siena, S. et al. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann Oncol 2004, 15(1): 113-7. (Pubitemid 38139611)
40. Bollard, C.M., Gottschalk, S., Leen, A.M. et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007, 110(8): 2838-45.
41. Yamamoto, R., Nishikori, M., Kitawaki, T. et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008, 111(6): 3220-4.
42. Gandhi, M.K., Moll, G., Smith, C. et al. Galectin-1 mediated suppression of Epstein- Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood 2007, 110(4): 1326-9.
43. Klibi, J., Niki, T., Riedel, A. et al. Blood diffusion and Th1-suppressive effects of galectin-9- containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood 2009, 113(9): 1957-66.
44. Rautert, R., Schinkothe, T., Franklin, J. et al. Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)- independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma. Leuk Lymphoma 2008, 49(11): 2091-8.
45. Xu, J., Menezes, J., Prasad, U., Ahmad, A. Elevated serum levels of transforming growth factor beta1 in Epstein-Barr virus-associated nasopharyngeal carcinoma patients. Int J Cancer 1999, 84(4): 396-9.
46. Marshall, N.A., Christie, L.E., Munro, L.R., Culligan, D.J., Johnston, P.W., Barker, R.N., Vickers, M.A. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004, 103(5): 1755-62.
47. Baumforth, K.R., Birgersdotter, A., Reynolds, G.M. et al. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol 2008, 173(1): 195-204.
48. Ishida, T., Ishii, T., Inagaki, A. et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006, 66(11): 5716-22.
49. Gandhi, M.K., Lambley, E., Duraiswamy, J. et al. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T- cell function in Hodgkin lymphoma patients. Blood 2006, 108(7): 2280-9.
50. Schreck, S., Friebel, D., Buettner, M., Distel, L., Grabenbauer, G., Young, L.S., Niedobitek, G. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol 2009, 27(1): 31-9.
51. Tzankov, A., Meier, C., Hirschmann, P., Went, P., Pileri, S.A., Dirnhofer, S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center- like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008, 93(2): 193-200. (Pubitemid 351397707)
52. Lau, K.M., Cheng, S.H., Lo, K.W. et al. Increase in circulating Foxp3+CD4+CD25(high) regulatory T cells in nasopharyngeal carcinoma patients. Br J Cancer 2007, 96(4): 617-22.
53. Li, J., Zeng, X.H., Mo, H.Y. et al. Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy. PLoS One 2007, 2(11): e1122.
54. Diepstra, A., van Imhoff, G.W., Karim-Kos, H.E. et al. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol 2007, 25(21): 3101-8.
55. Lee, S.P., Constandinou, C.M., Thomas, W.A. et al. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition. Blood 1998, 92(3): 1020-30.
56. Lai, F.M., Cheng, P.N., Tsao, S.Y., Lai, K.N. Immunohistological characteristics of the infiltrating lymphoid cells and expression of HLA class I and II antigens in nasopharyngeal carcinoma. Virchows Arch A Pathol Anat Histopathol 1990, 417(4): 347-52.
57. Ogino, T., Moriai, S., Ishida, Y. et al. Association of immunoescape mechanisms with Epstein-Barr virus infection in nasopharyngeal carcinoma. Int J Cancer 2007, 120(11): 2401-10. (Pubitemid 46642127)
58. Lee, S.P., Chan, A.T., Cheung, S.T. et al. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells. J Immunol 2000, 165(1): 573-82.
59. Kelly, G.L., Rickinson, A.B. Burkitt lymphoma: revisiting the pathogenesis of a virus-associated malignancy. Hematology Am Soc Hematol Educ Program 2007: 277-84.
60. Khanna, R., Burrows, S.R., Argaet, V., Moss, D.J. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. Int Immunol 1994, 6(4): 639-45.
61. Paludan, C., Bickham, K., Nikiforow, S. et al. Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J Immunol 2002, 169(3): 1593-603. (Pubitemid 34809208)
62. Voo, K.S., Fu, T., Heslop, H.E., Brenner, M.K., Rooney, C.M., Wang, R.F. Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. Cancer Res 2002, 62(24): 7195-9.
63. Leung, C.S., Haigh, T.A., Mackay, L.K., Rickinson, A.B., Taylor, G.S. Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display. Proc Natl Acad Sci U S A 2010, 107(5): 2165-70.
64. Paludan, C., Schmid, D., Landthaler, M., Vockerodt, M., Kube, D., Tuschl, T., Munz, C. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 2005, 307(5709): 593-6.
65. Moormann, A.M., Heller, K.N., Chelimo, K. et al. Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses. Int J Cancer 2009, 124(7): 1721-6.
66. Long, H.M., Zuo, J., Leese, A.M., Gudgeon, N.H., Jia, H., Taylor, G.S., Rickinson, A.B. CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein- Barr virus-transformed B cells. Blood 2009, 114(4): 807-15.
67. Johnson, L.A., Morgan, R.A., Dudley, M.E. et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114(3): 535-46.
68. Morgan, R.A., Dudley, M.E., Wunderlich, J.R. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314(5796): 126-9.
69. Sadelain, M., Brentjens, R., Riviere, I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009, 21(2): 215-23.
70. Pule, M.A., Savoldo, B., Myers, G.D. et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008, 14(11): 1264-70.
71. Bargou, R., Leo, E., Zugmaier, G. et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008, 321(5891): 974-7.
72. Bollard, C.M., Cooper, L.J., Heslop, H.E. Immunotherapy targeting EBV-expressing lymphoproliferative diseases. Best Pract Res Clin Haematol 2008, 21(3): 405-20.
73. Rosenberg, S.A., Restifo, N.P., Yang, J.C., Morgan, R.A., Dudley, M.E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008, 8(4): 299-308.
74. Di Stasi, A., De Angelis, B., Rooney, C.M. et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009, 113(25): 6392-402.
75. Foster, A.E., Dotti, G., Lu, A. et al. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother 2008, 31(5): 500-5.
76. Chakraborty, M., Abrams, S.I., Coleman, C.N., Camphausen, K., Schlom, J., Hodge, J.W. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004, 64(12): 4328-37. (Pubitemid 38802440)
77. Lee, Y., Auh, S.L., Wang, Y. et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009, 114(3): 589-95.